Search research articles
Contact Us
Filters
Showing results (41-50 of 164) with videos related to
Page
of 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2003
Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphoma
George Z Rassidakis, Andre Goy, L Jeffrey Medeiros, et al.
Clinical Immunology (Orlando, Fla.)
|
June 15, 2014
A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics
Carla Casulo, Julie M Vose, William Y Ho, et al.
Leukemia & Lymphoma
|
August 5, 2011
A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma
Anne W Beaven, Thomas C Shea, Dominic T Moore, et al.
Leukemia & Lymphoma
|
January 3, 2013
A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study
Francine M Foss, Nelida Sjak-Shie, Andre Goy, et al.
Oncotarget
|
August 22, 2015
Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine
Mohamed R Akl, Poonam Nagpal, Nehad M Ayoub, et al.
British Journal of Haematology
|
April 23, 2016
A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy
Andre Goy, Andres Forero, Nina Wagner-Johnston, et al.
Hemasphere
|
June 24, 2022
Phase 1b Dose-finding Study of Venetoclax With Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Alessandra Petrillo, Andrew Ip, Alexandra Della Pia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2013
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study
Andre Goy, Rajni Sinha, Michael E Williams, et al.
Breast Cancer : Basic and Clinical Research
|
October 4, 2023
Homologous Recombination Abnormalities Associated With <i>BRCA1/2</i> Mutations as Predicted by Machine Learning of Targeted Next-Generation Sequencing Data
Maher Albitar, Hong Zhang, Andrew Pecora, et al.
Oncotarget
|
March 24, 2016
Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies
Mohamed R Akl, Poonam Nagpal, Nehad M Ayoub, et al.
Page
of 17
Search research articles
Search
Showing results (41-50 of 164) with videos related to
Sort By:
Page
of 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2003
Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphoma
George Z Rassidakis, Andre Goy, L Jeffrey Medeiros, et al.
Clinical Immunology (Orlando, Fla.)
|
June 15, 2014
A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics
Carla Casulo, Julie M Vose, William Y Ho, et al.
Leukemia & Lymphoma
|
August 5, 2011
A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma
Anne W Beaven, Thomas C Shea, Dominic T Moore, et al.
Leukemia & Lymphoma
|
January 3, 2013
A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study
Francine M Foss, Nelida Sjak-Shie, Andre Goy, et al.
Oncotarget
|
August 22, 2015
Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine
Mohamed R Akl, Poonam Nagpal, Nehad M Ayoub, et al.
British Journal of Haematology
|
April 23, 2016
A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy
Andre Goy, Andres Forero, Nina Wagner-Johnston, et al.
Hemasphere
|
June 24, 2022
Phase 1b Dose-finding Study of Venetoclax With Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Alessandra Petrillo, Andrew Ip, Alexandra Della Pia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 5, 2013
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study
Andre Goy, Rajni Sinha, Michael E Williams, et al.
Breast Cancer : Basic and Clinical Research
|
October 4, 2023
Homologous Recombination Abnormalities Associated With <i>BRCA1/2</i> Mutations as Predicted by Machine Learning of Targeted Next-Generation Sequencing Data
Maher Albitar, Hong Zhang, Andrew Pecora, et al.
Oncotarget
|
March 24, 2016
Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies
Mohamed R Akl, Poonam Nagpal, Nehad M Ayoub, et al.
Page
of 17